chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Arm pain, fever, severe chills, headache, malaise, joint pain, general muscle pain, fatigue
Patient was brought to the ED by EMS on 10/28 after waking up early in the morning with diarrhea, then collapsing to the ground when she got out of bed due to weakness. She was on the ground for several hours. Patient tested positive for COVID-19 by PCR while in the ED on 10/28. She was admitted for generalized weakness, headache, and diarrhea from 10/28-11/8. She has received the COVID primary series vaccine.
RASH VERY ITCHY AND THERE ARE LITTLE RED DOTS LIKE A VEIN PROBLEM AROUND IT; LEG HURT LIKE THERE IS A PRESSURE INSIDE; LITTLE EDEMA WHERE SHE HAS A RASH; WEIRD CRAWLING SENSATION IN SKIN ON RASH AREA; RASH ON LEFT LEG BETWEEN ANKLE AND KNEE; STRANGE FEELING OF TINGLY SENSATION OF THE WHOLE LEG; This spontaneous report received from a patient concerned a 73 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Z05A21A, expiry: UNKNOWN) dose was not reported, administered on 30-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 22-JUN-2021, the patient experienced rash on left leg between ankle and knee. On 22-JUN-2021, the patient experienced strange feeling of tingly sensation of the whole leg. On 20-JUL-2021, Laboratory data included: Venous Doppler (NR: not provided) The blood test ruled out a blood clot. On 03-AUG-2021, Laboratory data included: Ankle brachial index (NR: not provided) Negative for claudication. On an unspecified date, the patient experienced weird crawling sensation in skin on rash area, rash very itchy and there are little red dots like a vein problem around it, leg hurt like there is a pressure inside, and little edema where she has a rash. Laboratory data (dates unspecified) included: Blood test (NR: not provided) Ruled out having cellulitis or diabetes. Treatment medications (dates unspecified) included: mupirocin. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from rash on left leg between ankle and knee, and rash very itchy and there are little red dots like a vein problem around it, and the outcome of strange feeling of tingly sensation of the whole leg, weird crawling sensation in skin on rash area, leg hurt like there is a pressure inside and little edema where she has a rash was not reported. This report was non-serious.
Heart palpitations not normal; rash around site; dizziness; low fever; nausea; sweating; body ache; fatigue; This is a spontaneous report from a non-contactable Nurse. The nurse reported for herself that a 41-year-old non-pregnant female patient received first dose of BNT162B2 (Pfizer-Biontech COVID-19 Vaccine, solution for injection, Lot Number: EN9581), via intramuscular route of administration at left arm on 03Feb2021 at 15:00 (at the age of 41-year-old), as single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. Other medications in two weeks were reported as yes but not specified. Patient had no known allergies. The patient was not pregnant at the time of vaccination. It was unknown if other vaccine received by patient within four weeks. No Covid tested post as well as prior vaccination., The patient experienced heart palpitations not normal, rash around site, dizziness, low fever, nausea, sweating, body ache and fatigue on 04Feb2021 at 06:00 AM. No treatment provided for the events. The outcome of the events was recovering.  No follow up attempts are possible. No further information is expected.
16mins post vaccination pt c/o dizziness and pressure to the top/back of the head. Vitals: 115/64, 65, 14 Pt given water, rest and monitoring.  Pt stable and released from the vaccination site @09:15
This spontaneous report as received from a medical assistant refers to multiple unspecified patients of unknown age and gender. The concurrent conditions and medical history of the patients were not reported. On an unknown date, the patients were vaccinated with a dose of improperly stored PROQUAD subcutaneously (strength and dose were unknown). The lot number was L040415 with expiration date of 04-APR-2-17. There were no concomitant therapies nor adverse effects reported. This case is one of two cases from the same reporter. Additional information has been requested.
arm a little swollen; arm was hot/ it was really hot; the arm started to hurt again; The lymph nodes in her arm were also sore; muscles were aching; injection site soreness; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (arm a little swollen), FEELING HOT (arm was hot/ it was really hot), PAIN IN EXTREMITY (the arm started to hurt again), LYMPHADENOPATHY (The lymph nodes in her arm were also sore) and MYALGIA (muscles were aching) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, the patient experienced VACCINATION SITE PAIN (injection site soreness). On 01-May-2021, the patient experienced PERIPHERAL SWELLING (arm a little swollen), FEELING HOT (arm was hot/ it was really hot), PAIN IN EXTREMITY (the arm started to hurt again), LYMPHADENOPATHY (The lymph nodes in her arm were also sore) and MYALGIA (muscles were aching). At the time of the report, PERIPHERAL SWELLING (arm a little swollen), FEELING HOT (arm was hot/ it was really hot), PAIN IN EXTREMITY (the arm started to hurt again), LYMPHADENOPATHY (The lymph nodes in her arm were also sore), MYALGIA (muscles were aching) and VACCINATION SITE PAIN (injection site soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were  not provided. Treatment information was not provided.
Nausea, sore throat, fever, sweating profusely, extreme rib pain, coughing, left jaw locked, flu-like aches, left arm gave out. Time = current on going, not yet recovered.
Patient given immunizations @ 10:55 and reported felt light headed and loss balance. Face red,hands shaking,cold &clammy, eyes glazed, unware of her surroundings. Doctor responded. Vital signs recorded Q 5 minutes BP 96/56 pulse 72(normal for patient) Oxygen given @ 2 liters Monitored until 11:45 and released to return on 07/17/2008 for follow-up
NONE - parents wanted vaccine for their new 12 year old even though it was age 5-11
Fever of 100.1, body aches, nausea. loss of appetite. Fever has gone down, to 99.1
Complained of severe headache above behind right eat 3 hours after receiving vaccine. Describes pain as dull to sharp comes and goes. Alleve doesn't help, no trouble with vision. Also complained of aea being "numb-tingles" for at last one week.
pt recv vax 19AUG96 & 21NOV96 pt devel vesicular chickenpox lesions w/10 to 15 pox on face, some scattered on trunk & a few on arms & legs;there was a mild number of papula;
Tested COVID + 9/20/21. Came to hospital 9/22/2021 because of worsening shortness of breath. Very hypoxic Intubated 10/8/21 and quickly declined requiring CRT and vasopressors for shock. Expired 10/15/2021.
expired dose was given; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a patient who received DTPa (Infanrix) (batch number 4L9E4, expiry date 07-FEB-2023) for prophylaxis.   On 03-MAR-2023, the patient received Infanrix. On 03-MAR-2023, an unknown time after receiving Infanrix, the patient experienced expired vaccine used (Verbatim: expired dose was given). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 07-MAR-2023 HCP reporting via webform.  The reporter reported that an expired dose of Infanrix was given to the patient.  No additional adverse event information was available.  The reporter reported that an expired dose of Infanrix was given to the patient, which led to expired vaccine used. The case had been linked to US2023035910, reported by the same reporter, for a different patient.; Sender's Comments:  US-GSK-US2023035910:same reporter
Patient experienced syncope a few minutes following receiving his first dose Pfizer, Lot EW0164.  Patient reported queasiness immediately prior. Vitals: immediately after BP 63/47, HR 66, SpO2 96%. Provided patient with cold water, towels. Vitals: BP 68/31, HR 100; Moved him to pharmacy where it was cooler. Vitals: 119/65, HR 74. Repeat BP 127/71. Provided patient with sprite, wet towels, and popsicle. Family picked patient up.
Localized redness/swelling/pain with/w localized allergic reaction (approx. 1 week of sxs). Rx: ZYRTEC 10 mg bid.
Around 9/9/22, he started getting nasal congestion and a cough. We took him to the doctor 9/23/22. We took him to the doctor, and they diagnosed an ear infection. They prescribed amoxicillin. This lasted for about 3 weeks. Then on 1/6/23, he had a fever cough, vomiting and diarrhea. We took him to the doctor and COVID-19 was ruled out. He suspected that it was Adenovirus. This continued through 1/25/23. He started tugging at his ears and we took him to the doctor again and he was diagnosed with a double ear infection 1/30/23. They prescribed amoxicillin again. He got better, then on 2/10/23 he started getting stuffy again, coughing, and runny nose. He started vomiting yesterday and had a mild fever. We kept home from daycare, but we have not taken him to the doctor for this yet. It is still very new.
Information has been received from a nurse practitioner (N.P.) concerning her 9 year old daughter with no pertinent medical history and drug allergies who on 11-JUL-2000 and 03-FEB-2009 was vaccinated SQ with a first dose and second 0.5ml dose of VARIVAX (Merck) (lot # 635441/0122K for dose 1, lot # 662148/1528X for dose 2). There was no concomitant medication. On 07-FEB-2009 the patient experienced headache, body aches and a fever. On 08-FEB-2009 the patient experienced rash on chest, back, arm and legs. The nurse practitioner reported that the patient had chickenpox. There are 12 lesions noted. No lab tests were performed. As of 09-FEB-2009, the patient was not recovered. Follow-up information was received from the nurse practitioner on 11-FEB-2009 which reported that currently the patient had 25 little poxes. Follow-up information was received from the NP who is the patient's mother. It was reported that the 9 year old female patient with no relevant medical history who on 11-JUL-2000 and at 3:00 pm 03-FEB-2009 was vaccinated SQ with a first dose and second 0.5ml dose of VARIVAX (Merck) (lot # 635441/0122K for dose 1, lot # 662148/1528X for dose 2). The second dose was vaccinated into the left arm. There was no illness at the time of vaccination. Subsequently the patient started with headache and fever 4 days after the vaccination, on 07-FEB-2009. On the 5th day, 08-FEB-2009, the patient developed a vesicular rash. It was reported that "no school or work for 4 days". The patient also had mild respiratory symptoms started around the 7th day, on approximately 10-FEB-2009. On 13-FEB-2009 the patient recovered. Additional information has been requested.
Pt has been coughing and wheezing since the day after she got her flu mist.
Initial and follow up information has been received from Merck pregnancy registry and from a 17 year old female consumer who on 15-MAR-2007 was vaccinated with a first dose of Gardasil. Patient had an ultrasound and later it was determined she was pregnant. The LMP date was 16-FEB-2007, with an estimated due date of 23-NOV-2007. On 15-MAR-2007 the patient reported that she experienced a fever, feeling hot in the night time and little nausea. She also noticed a clear white discharge from the vagina. The patient sought unspecified medical attention. At the time of this report, the outcome of the event was unknown. Additional information has been requested. This is in follow-up to report (s) previously submitted on 5/14/2007.  Initial and follow up information has been received from a pregnancy registry, a nurse practitioner and a 17 year old female patient who on 15-MAR-2007 was vaccinated with a first dose of GARDASIL vaccine lot #653938/0954F. Concomitant therapy included ascorbic acid (+) cholecalciferol (+) folic acid (+) iron (unspecified) (+) vitamin A acetate (+) vitamin B complex (+) vitamin E acetate (NATAPORT PRENATAL VITAMIN. On 10-Apr-2007, patient had an ultrasound and later it was determined she was pregnant 71/weeks. Her last menstrual period (LMP) date was 16-FEB-2007, with an estimated due date of 23-NOV-2007. On 15-MAR-2007 the patient reported that she experienced a fever, feeling hot in the night time and little nausea. She also noticed a clear white discharge from the vagina. The patient sought unspecified medical attention. At the time of this report, the outcome of the event was unknown. Follow up information indicated that on 13-JUN-2007 maternalserum alfa fetoprotein (MSAFP) laboratory test was done and it was negative X 4. During the pregnancy on 10-JUL-2007 an ultrasound revealed anatomical survey was normal. In follow up the nurse practitioner reported that the patient had a low transverse cervical section (LTCS) was done for fetal bradycardia and nonreassuring fetal heart tones (FHT's). It was reported that she had 1 -> LTCS for persistant variable decelerations and "bradychardia ". On 27-NOV-2007 patient delivered a normal female baby who weighed 7 pounds, 4 ounces and 49 cm in length and she was "40.4/7" weeks from her LMP. The Apgar score of the baby was 7/9 and her head circumference was 33 centimeter. Upon internal review indication for Cesarean Section due to fetal bradycahrdia and persistance variable deceleration fetal heart tone were determined to be an other important medical events. Additional information is not expected.
Patient report she has hives all over her body, did not develop until later after leaving facility, the next day. States has has blotches all over face and arms.
My feet and toes feel numb; My feet and toes feel numb; One nail is like almost off; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (003110). The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date 15Jan2022 (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Dose number 1, Manufacturer- Unknown), for COVID-19 immunization; Covid-19 vaccine (Dose number 2, Manufacturer- Unknown), for COVID-19 immunization. The following information was reported: HYPOAESTHESIA (non-serious), HYPOAESTHESIA (non-serious) all with onset Jan2022, outcome "not recovered" and all described as "My feet and toes feel numb"; NAIL AVULSION (non-serious) with onset Jan2022, outcome "unknown", described as "One nail is like almost off".  The lot number for bnt162b2 was not provided and will be requested during follow up.
Patient received a second influenza immunization this season. He reports he did not have any adverse events.
Low grade fever, cold chills, sever headache and body ache.  Flu like symptoms.
Received Pfizer vaccines on 3/25/21, 4/20/21 Tested positive for COVID by PCR on 1/7/21 admitted to hospital on 1/5/22 d/t SOB, fever, weakness underlying AML  previously COVID positive in October 2021, rehospitalized in December 2021 d/t persistent pneumonia
dizziness; This spontaneous case was reported by a patient and describes the occurrence of DIZZINESS (dizziness) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination.     No relevant medical history was reported.     On 10-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-May-2021, the patient experienced DIZZINESS (dizziness). At the time of the report, DIZZINESS (dizziness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.   No treatment medication was reported.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessment.
TACHYCARDIA IN 220'S, SHORTNESS OF BREATH, HIVES,DIFFICULTY BREATHING, AIR WAY CLOSURE: occuring approximately 45 minutes after injection. EMS  was called and Benadryl was and EPI on hand.   Primary care order Epi on hand prior to vaccine appt and Benadryl to be taken.
This case was reported by a consumer via call center representative and described the occurrence of light headedness in a 74-year-old female patient who received SHINGRIX for prophylaxis. Concurrent medical conditions included breast cancer (radiation treatment). On 2nd April 2018, the patient received the 1st dose of SHINGRIX (intramuscular) .5 ml. On 2nd April 2018, less than a day after receiving SHINGRIX, the patient experienced light headedness and injection site pain. SHINGRIX was continued with no change. On an unknown date, the outcome of the light headedness and injection site pain were recovered/resolved. It was unknown if the reporter considered the light headedness and injection site pain to be related to SHINGRIX. Additional details reported as follows: The patient planned to follow-up with her physician on an unknown date.
I have gone through menopause and hadn't had a period in two full years. I got my period about a month after the first Pfizer COVID injection complete with cramps. The period was similar to periods I used to get which is is a light period that lasts a couple days. (I wouldn't have related this event to these shots but then saw a BBC article about this affect on women.)
Palpitations , heart rate went up to 140 , strong chest pain specifically on the left side ,  pain when inhaling , and movement .  Chest still currently  hurts  when power walking or running .
#2 Anthrax injection next day reports swelling and redness @ injection site right upper arm. Now presents with redness, more pink than bright red from top of tricep to approximate 1" below elbow, soft Induration 4cm x 4 cm @ injection site.  Injections site from #1 injection left upper arm 2cm x 2cm induration, no redness, no change since 6/8/05.  Denies fever, GI upset, no body aches, no change in appetite.  Right axilla non tender, no nodules palpable.  Taking 400 mg. IBU TID and Benadryl 50 mg x3 doses. Needs Anthrax Immunization for work. No exacerbation of Asthma Symptoms.
Patient developed chest pain about 27 hours after 2nd Pfizer vaccine.  Central chest pain, not reproducible.  She went to ED on 4/23/21 and had evaluation including D-dimer which was  above 4000.  Recheck on 4/26/21, D-dimer level was 177.  Imaging studies and other labs negative.
After vaccinating Pt. within 2 hrs. her (R) outer side of her arm became extremely sore and had symptoms of fever and nausea. The following morning upon rising pt.'s (R) outer arm had swollen to a fist sized hard, red, hot and sore knot. The surrounding area of the (R) upper arm had generalized erythemia when she reported H.D. On 6-14-13. Pt. C/O pruritus.
This patient had cellulitis and erythema bruise at the injection site on her right leg. Sent to ER for follow up.
needed revaccination dues to titers being low and had to return back to college; 22 year old patient received 0.5 ml of RECOMBIVAX, in result of a misuse, the adult dose was 1 .0 ml; The patient has already completed the series for hepatis B in the past, unknown by reporter exact date, needed revaccination dues to titers being low and has to return back to college; This spontaneous report was received from a physician, concerning a 22-year-old patient of unknown gender. No information was provided regarding the patient's pertinent medical history, concomitant medications and drug reactions or allergies.  On an unspecified date (reported as in the past), the patient completed the vaccination scheme for hepatitis B. However, the patient needed revaccination due to titers being low (hepatitis b surface antibody negative) and had to return back to college. So, on 12-OCT-2020, the patient received hepatitis b vaccine (recombinant)(RECOMBIVAX HB), at a dose of 0.5 ml for prophylaxis (strength, route of administration, lot number and expiration date were not reported) in result of a misuse, the adult dose was 1.0ml (incorrect dose administered and inappropriate schedule of product administration).
Patient arrives to obs; PT states patient felt lightheaded.  Patient reports feeling high, VS 212/98,C   127, 100% frightened breathing shallow and quickly. Emotional support given, transported to stretcher.  BP   189/104 hr 105 99% awake and alert.  Continues to repot lightheadedness.  She states walking down from vaccination she had an aura type experience.  10:50 BP 214/97HR 104, 99%, Respiratory arrived.   Followed by MD and IV nurse.  10:55  213/88 HR92 99%.  Transferred to ER by IV Nurse and administrator.
Shingles; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (Shingles) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HERPES ZOSTER (Shingles). At the time of the report, HERPES ZOSTER (Shingles) outcome was unknown.            The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was not applicable.  No relevant concomitant medications was reported.  Treatment information was not provided
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 63-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 16Nov2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 62 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Sulfa Allergy" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid treatment from 24Jun2023 to 28Jun2023.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Rash, fever began on the night after receiving immunization. As of 11/21/16, symptoms are improving - according to patient.
2 days post vaccination (flu) red rash down left arm; minimal swelling; no warmth.
Hives.  Treated with benadryl. Seen in office 5/29/21.  Referred to allergist.  5/31/21 seen in ER for lip swelling and hives thought to be possible due to viral infection since had two liquid stools on 5/31/21.  Seen in office 6/8/21.  Has upcoming allergist appt.